Tongjitang Chinese Medicines Company reported that its Q1 revenues and profits were lower than a year ago. The company blamed the heavy February snowfalls as the reason behind the disappointing quarterly results, even though the rest of China biopharma was largely able to dramatically increase its sales and net income in the same period. More details...

Stock Symbol: (NYSE: TCM)